Please assess the completion status of the following clinical trial:

Trial Title: Dendritic Cell Based Therapy of Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven progressive metastatic or locally advanced breast cancer~* No standard treatment indicated~* Age: \> 18~* WHO-Performance Status 0-1~* At least tone measurable tumor lesions according to the RECIST criteria.~* Expression of the HLA-A2 tissue type~* Life expectancy more than 3 months~* Acceptable CBC and blood chemistry results~* Written informed consent~Exclusion Criteria:~* Patients with a history of any other neoplastic disease less than 5 years ago (excepting treated carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin).~* Patients with metastatic disease in the central nervous system (CNS).~* Patients with other significant illness including severe allergy, asthma, angina pectoris or congestive heart failure.~* Patients with acute or chronic infection including HIV, hepatitis and tuberculosis.~* Patients who are pregnant.~* Patients who have received antineoplastic therapy including chemotherapy or immunotherapy less than 4 weeks before beginning the trial.~* Patients who receive corticosteroids or other immunosuppressive agents.~* Patients with active autoimmune diseases such as lupus erythematosus, rheumatoid arthritis or thyroiditis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).